Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results (CROSBI ID 322048)

Prilog u časopisu | izvorni znanstveni rad | domaća recenzija

Guteša, Ilija ; Potesak, Ivana ; Pavičić, Ivana ; Tometić, Gordan ; Kirac, Iva ; Penavić, Ivan ; Milas, Ivan ; Stanec, Mladen Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results // Libri oncologici : Croatian journal of oncology, 44 (2016), 2-3; 15-19

Podaci o odgovornosti

Guteša, Ilija ; Potesak, Ivana ; Pavičić, Ivana ; Tometić, Gordan ; Kirac, Iva ; Penavić, Ivan ; Milas, Ivan ; Stanec, Mladen

engleski

Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results

Segmentectomy and sentinel lymph node biopsy is a golden standard for early breast cancer (clinical and radiological cT1-2, c N0). Recently, superparamagnetic iron oxide (SPIO) nanoparticle tracer has been introduced enabling intraoperative tracer injection. We prospectively recorded data on tumor histology, marked lymph nodes and their final histology and patient characteristics for early breast cancer patients who underwent breast conservative surgery. At 128 female breast cancer patients underwent sentinel lymph node biopsy by SentiMag. Three patients were excluded from further analysis because the postoperative pathology report was ductal carcinoma in situ (DCIS). The identifi cation rate was 95.2 % (119 of 125). Of the 19.2 % (24 of 125) patients with lymph node involvement, 1.6% (2 of 125) had micrometastasis, and 1 % (1 of 125) had single tumor cells within the sentinel, l at least a micrometastasis. Of 30 positive lymph nodes removed, 24 (80 %) were true sentinel nodes. The average lymph node retrieval rate was 2.3 nodes per patient. SentiMag’s performance was comparable to published data and to standard sentinel with blue patent die and/or technetium. The benefi t of easier application and logistics is a great advantage.

SentiMag ; Sienna+® ; superparamagnetic iron oxide ; early breast cancer

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

44 (2-3)

2016.

15-19

objavljeno

0300-8142

2584-3826

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost